No Data
No Data
No Data
No Data
No Data
復銳醫療科技:2023年度報告
Futu News29minutes ago · Announcements
Fu Rui Medical Technology (01696) Innovative Hyaluronic Acid Product Profhilo Launched in Hainan
Profhilo is an innovative hyaluronic acid that corrects/fills natural and induced skin depressions to help ease the physiological process of skin aging, including reducing skin hydration, adjusting dermal elastic fibers and collagen, and improving skin filling defects and dull skin tone.
Zhitong FinanceApr 24 13:14
Express News | General Administration of Market Regulation: Maintain a high-pressure crackdown on illegal acts of medical and aesthetic advertising and strictly regulate the publication of medical and aesthetic advertisements
BreakingsApr 9 16:06
FuRui Medical Technology (01696.HK): 2023 results are under pressure, and we expect China to strengthen the registration and filling business
The 2023 results fell short of our expectations. The company announced 2023 results: revenue of US$359 million, +1.4% YoY; adjusted net profit of US$37.48 million, or -22.9% YoY. Due to macroeconomic factors in many regions
中金公司Mar 24 00:00
FuRui Medical Technology (01696.HK): Short-term performance disrupts during the transition period, concerns the injection sector is ready to go
Event: FuRui MedTech discloses 2023 results: 2023: Company revenue of $359 million (+1.4%) and net profit of $33 million (-17.9%) despite global challenges in 2023
方正證券Mar 24 00:00
FuRui Medical Technology (01696.HK): Short-term performance under multiple factors, pressure-pressurized injection lines are about to be approved domestically
Event: The company released its 2023 annual report. In 2023, we achieved revenue of US$359 million, up 1.4% year over year; realized adjusted net profit of US$38 million, down 22.9% year over year. Profit level: Increased gross margin
財通證券Mar 22 00:00
No Data
No Data